Clinical trials: Inhalation
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler
The aim of this non-interventional study is to ensure that patients in routine clinical practice follow given treatment instructions and to evaluate the number of reliever inhalations as well as the number of patient/days with…
- Trial name
- SYMCO (NCT00557297)
- Where
- 22 sites in Latvia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Respiratory Morbidities of Prematurity (RMP)
Open-label Study of Inhaled RVT-1601 in Preterm Infants
Preterm birth predisposes infants to greater risk for respiratory morbidities and the need for pulmonary care compared to term infants both in the short-term and long-term.
- Trial name
- NCT04007120
- Testing
- RVT-1601
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Respivant Sciences GmbH
Sleep Apnea, Obstructive
Comparison of Breathing Events Detected by the SleepStyle 200 Auto Continuous Positive Airway Pressure (CPAP) Device to Attended Polysomnography
Obstructive Sleep Apnoea (OSA) is a common sleep-breathing disorder affecting around 2-4% of the population and is characterised by loud snoring, periodic collapse of the upper airway particular to sleep, sleep fragmentation, and…
- Trial name
- NCT00697424
- Testing
- SleepStyle 200 Auto Series CPAP Humidifier
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Fisher and Paykel Healthcare
Asthma
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
- Trial name
- NCT01090024
- Testing
- BI 671800
- Where
- 14 sites in United States
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Ischemia-Reperfusion Injury
Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation
The purpose of this study is to evaluate the effects of inhaled nitric oxide on both short-term physiology as well as on the development of ischemia-reperfusion lung injury (IRLI) in the immediate post transplant period.
- Trial name
- NCT00060450
- Testing
- nitric oxide for inhalation
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mallinckrodt
Pulmonary Hypertension Associated With Interstitial Lung Disease
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period.
- Trial name
- SERANATA (NCT07181382)
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 4 sites in United States, Israel
- Volunteers
- 480 people
- Sponsor
- GB002, Inc.
Mycobacterium Infections, Nontuberculous
Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
The trial is an open-label, non-controlled, multicenter, pilot clinical trial of inhaled molgramostim (recombinant human granulocyte-macrophage colony stimulating factor; rhGM-CSF) in subjects with persistent pulmonary…
- Trial name
- OPTIMA (NCT03421743)
- Testing
- Inhaled molgramostim, Antimycobacterial regimen
- Where
- 5 sites in Australia, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Savara Inc.
Cystic Fibrosis (CF)
Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers
This study will be performed to assess the safety, tolerability and PK of escalating inhaled AIR-DNase doses administered as a single dose followed by multiple doses for 5 consecutive days in healthy subjects.
- Trial name
- NCT02605590
- Testing
- AIR DNase
- Where
- Israel
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Protalix
Asthma
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
- Trial name
- NCT01766843
- Testing
- Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Periodic Breathing, Breathing-Related Sleep Disorder
Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV
This study will determine if modified adaptive servoventilation (ASV) is as effective as the conventional ASV in treating periodic breathing.
- Trial name
- NCT01405313
- Testing
- Modified Adaptive Servoventilation Device, Conventional Adaptive Servoventilation device
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- ResMed
Asthma
Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.
- Trial name
- NCT01593826
- Testing
- Charcoal and Budesonide/formoterol Easyhaler 320/9 microg, Charcoal and Symbicort Turbuhaler, Budesonide/formoterol Easyhaler 320/9 microg
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Pulmonary Disease, Chronic Obstructive
Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)
What are the differences between patients prescribed a new maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD) with tiotropium/olodaterol (TIO/OLO) or Inhaled Corticosteroids (ICS)-containing regimens in terms…
- Trial name
- NCT04402515
- Testing
- TIO/OLO, ICS
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic…
- Trial name
- NCT01336608
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 72 sites in United States, Germany and 4 more
- Volunteers
- 446 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease (PD), Parkinson's Disease
Real-world Patient Experiences With Inbrija®
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing.
- Conditions
- Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
- Trial name
- INHALE-PD (NCT07797790)
- Testing
- Levodopa inhalation powder
- Where
- 2 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Merz Therapeutics GmbH
Pulmonary Disease, Chronic Obstructive, Asthma
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of Berodual delivered via the…
- Trial name
- NCT00153075
- Testing
- Berodual Respimat, Berodual HFA-MDI
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
The purpose of this trial is to evaluate the safety and effectiveness of one dose strength of Denufosol compared to placebo in patients with CF and a predicted FEV1 of greater than or equal to 75% but less than or equal to 110%…
- Trial name
- NCT00625612
- Testing
- Denufosol Tetrasodium (INS37217) Inhalation Solution
- Where
- 106 sites in United States, Australia and 2 more
- Volunteers
- 466 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Pharmacokinetics
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers
The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.
- Trial name
- NCT01181700
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Singapore
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pfizer
Aspergillosis, Lung Transplant Infection
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
This study tests the effects of pre-emptive treatment with an experimental drug PC945 in lung transplant recipients whose lungs are infected by the fungus Aspergillus fumigatus.
- Trial name
- NCT03905447
- Testing
- PC945, Standard of Care
- Where
- 3 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Pulmocide Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.